Pyxis Oncology (PYXS) FCF Margin (2024 - 2025)

Pyxis Oncology (PYXS) posted quarterly FCF Margin of 94.46% for Q4 2025, up 84.57% quarter-over-quarter from 612.16% in Q2 2025.

Pyxis Oncology (PYXS) FCF Margin (2024 - 2025) Analysis & Trends

Pyxis Oncology (PYXS) has reported FCF Margin for 2 consecutive years, with 94.46% the latest figure, recorded in Q4 2025.

In Q4 2025, FCF Margin changed N/A year-over-year to 94.46%; the TTM figure through Dec 2025 stood at 458.23% (down 9958.0% YoY), while the FY2025 annual figure was 458.3%, down 9964.0% from the prior year.
FCF Margin grew to 94.46% in Q4 2025 per PYXS's latest filing, from 612.16% in the prior quarter.
Across five years, FCF Margin topped out at 94.46% in Q4 2025 and bottomed at 612.16% in Q2 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	FCF Margin (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn	30.39%
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn	13.35%
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn	-
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn	-388.28%
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn	25.68%
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn	22.62%
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn	-22.35%
8	Royalty Pharma	26.98 Bn	26.14 Bn	-	70.82%
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn	41.07%
10	Pyxis Oncology	199.01 Mn	166.02 Mn	-	-

Download Data